Human neutralizing monoclonal antibodies to respiratory syncytial virus
AssigneeThe Scripps Research Institute
InventorsDennis R. Burton, Carlos F. Barbas, III, Robert M. Chanock, Brian R. Murphy, James E. Crowe, Jr.
Life of this patent
Estimating the term…
Abstract
A method for providing passive immmunotherapy to respiratory syncytial virus (RSV) disease in a host is disclosed. The method includes administering to a host a human monoclonal antibody Fab fragment that neutralizes both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV), or a monoclonal antibody comprising the fragment.
Claims16
A method for providing passive immunotherapy to respiratory syncytial virus (RSV) disease in a host, comprising administering to the host an immunotherapeutically effective amount of 1) a hunan monoclonal antibody Fab fragment that neutralizes both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV), wherein the Fab fragment binds to an epitope present on glycoprotein F and is produced by ATCC 69072 or 2) a monoclonal antibody comprising said Fab fragment.
Dependencies are inferred from the claim text.